Молекула, яка змінила погляд на лікування шкіри
DOI:
https://doi.org/10.30978/UJDVK2021-4-44Ключові слова:
акне; місцеве лікування; ретиноїди; механізм дії; мікронізований третиноїн 0;05 %; гідрогелевий матрикс; лосьйон «Альтрено»ТМАнотація
Мета роботи — вивчити сучасну класифікацію, механізми дії та клінічні ефекти похідних вітаміну А, виявити ретиноїд для місцевого лікування різних дерматозів з універсальним механізмом дії на рівні епідермісу та дерми.
Матеріали та методи. Представлено огляд літератури та аналіз результатів міжнародних клінічних досліджень засобів на основі природного ретиноїду першого покоління — третиноїну (ретиноєвої кислоти). Проаналізовано роботи десятків авторів, починаючи з 80-х років минулого століття і дотепер. У більшості джерел наведено докладні відомості про результати топічних ретиноїдів у терапії акне, що є основою клінічних настанов. Проведені протягом останніх десятиріч довгострокові (від 6 міс і більше) дослідження препаратів на основі ретиноєвої кислоти, відкрили унікальні клінічні ефекти третиноїну в терапії фотостаріння шкіри, актинічного кератозу тощо. Вони досягаються завдяки впливу третиноїду на ядерні рецептори кератиноцитів та фібробластів.
Результати та обговорення. Систематизовано і згруповано в єдиний огляд молекулярні механізми дії ретиноєвої кислоти, які реалізують клітинні та тканинні ефекти найбільш вивченого ретиноїду. Доведено, що вибірковою відмінністю третиноїну є його унікальна особливість активувати безпосередньо всі підтипи RARs і опосередковано — RXRs-нуклеарні рецептори клітин шкіри. Представлено новий сучасний препарат для зовнішнього застосування — лосьйон «Альтрено»ТМ , який містить мікронізований третиноїн 0,05 % в поєднанні з натрію гіалуронатом, розчинним колагеном та гліцерином. Такий склад виявляє очікувану клінічну ефективність у терапії акне і попереджає побічні ефекти у вигляді сухості, почервоніння та лущення. «Альтрено»ТМ дозволений для використання у дітей з 9 років.
Висновки. Третиноїн (ретиноєва кислота) — сучасний потужний ретиноїд з універсальним механізмом дії, рекомендований для лікування акне.
Посилання
Abdulmajed K, Heard C. Topical delivery of retinyl-ascorbate co-drug 1. Synthesis, penetration, into and permeation across human skin. Int J Pharm. 2004;280:113-124.
Alirezai M, Dupuy R, Amblard P, et al. Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses. J Am Acad Dermatol. 1994;30:447-451.
Antille C, Tran C, Sorg O, et al. Penetration and metabolism of topical retinoids in ex-vivo organ-cultured full-thickness human skin explants. Skin Pharmacol Physiol. 2004;17:124-128.
Armstrong RB, Lesiewicz J, Harvey G, et al. Clinical panel assessment of photodamaged skin treated with isotretinoin using photographs. Arch Dermatol. 1992;128:352-356.
Aslam MN, Fligiel H, Lateef H, et al. PADMA 28: A multi-component herbal preparation with retinoid like dermal activity but without epidermal effects. J Invest Dermatol. 2005;124:524-529.
Astrom A, Tavakkol A, Pettersson U, et al. Molecular cloning of two human cellular retinoic acid-binding proteins (CRABP). J Biol Chem. 1991;266:17662-17666.
Barkovic S, Leyden JJ, Wu IT, et al. Clinical evaluation of topical retinol-dimethylenolamine (DEMA) treatments for aging skin. J Am Acad Dermatol. 2005;52(3:S1):27.
Baumann L, Vujevich J, Halem M, et al. Open-label pilot study of 0,1% alitretinoin gel in the treatment of photoaging. Cutis. 2005;76:69-73.
Bernstein EF, Uitto J. Connective tissue alterations in photoaged skin and the effects of alphahydroxy acids. J Geriatr Dermatol. 1995;3(A):7-18.
Bhawan J, Gonzalez-Serva A, Nehal K, et al. 1991. Effects of tretinoin on photodamaged skin. A histologic study. Arch Dermatol. 1991;27:666-672.
Bhawan J, Palco MJ, Lee J, et al. Reversible histologic effects of tretinoin on photodamaged skin. J Geriatr Dermatol. 1995;3:62-67.
Bhawan J, Olsen E, Lufrano L, et al. Histologic evaluation of the long-term effects of tretinoin on photodamaged skin. J Dermatol Sci. 1996;11:177-182.
Bodsworth NJ, Bloch M, Bower M, et al. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0,1 % in cutaneous AIDSrelated Kaposi’s sarcoma. Am J Clin Dermatol. 2001;2:77-87.
Brand MJ, Petkovich M, Krust A, et al. Identifi cation of a second human retinoic acid receptor. Nature. 1988;332:850-853.
Caputo R, Monti M, Motta S, et al. The treatment of visible signs of senescence: the Italian experience. Br J Dermatol. 1990;122(35):97-103.
Chandraratna R.A. Tazarotene-first of a new generation of receptor-selective retinoids. Br J Dermatol. 1996;135(49):18-25.
Cheer SM, Foster R.H. Alitretinoin. Am J Clin Dermatol. 2000;1:307-316.
Cook-Bolden FE, Weinkle SH, Guenin E, Bhatt V. Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic Population. J Drugs Dermatol. 2019;18(1):32-38.
Creidi P, Vienne MP, Ochonisky S, et al. Profilometric evaluation of photodamage after topical retinaldehyde and retinoic acid treatment. J Am Acad Dermatol. 1998;39:960-965.
Creidi P, Humbert P. Clinical use of topical retinaldehyde on photoaged skin. Dermatology. 1999;199(1):49-52.
Cuce LC, Bertino MC, Scattone L, et al. Tretinoin peeling. Dermatol Surg. 2001;27:12-14.
Cunningham WJ. Topical isotretinoin and photodamage. Dermatologica. 1990;181:350-351.
Date AA, Naik B, Nagarsenker MS. Novel drug delivery systems: potential in improving topical delivery of antiacne agents. Skin Pharmacol Physiol. 2006;19:2-16.
Didierjean I, Tran C, Sorg O, et al. Biological activities of topical retinaldehyde. Dermatology. 1999;1(1):19-24.
Diridollou S, Vienne MP, Alibert M, et al. Efficacy of topical 0,05% retinaldehyde in skin aging by ultrasound and rheological techniques. Dermatology. 1999;199(1):37-41.
DiSepio D, Ghosn C, Eckert RL, et al. Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Proc Natl Acad Sci USA. 1998;95:14811-14815.
Draelos S. Novel approach to the treatment of hyperpigmented photodamaged skin: 4 % hydroquinone/0,3 % retinol versus tretinoin 0,05 % emollient cream. Dermatol Surg. 2005;31:799-804.
Duell EA, Derguini F, Kang S, et al. Extraction of human epidermis treated with retinol yields retro-retinoids in addition to free retinol and retinyl esters. J Invest Dermatol. 1996;107:178-182.
Ellis CN, Weiss JJ, Hamilton TA, et al. Sustained improvement with prolonged topical tretinoin (retinoic acid) for photoaged skin. J Am Acad Dermatol. 1990;23:629-637.
Feinberg C, Hawkins S, Battaglia A, et al. Comparison of anti-aging efficacy from cosmetic ingredients on photoaged skin. J Am Acad Dermatol. 2004;50(3 : S1):27.
Fisher GJ, Talwar HS, Xiao JH, et al. Immunological identification and functional quantification of retinoic acid and retinoic X receptor proteins in the human skin. J Biol Chem. 1994;269:20629-20635.
Fisher GJ, Datta SC, Talwar HS, et al. The molecular basis of sun induced premature ageing and retinoid antagonism. Nature. 1996;379:335-338.
Fisher GJ, Wang ZQ, Datta SC, et al. Pathophysiology of premature skin aging induced by ultraviolet light. N Engl J Med. 1997;337:1419-1428.
Fluhr JW, Vienne MP, Lauze C, et al. Tolerance profi le of retinol, retinaldehyde and retinoic acid under maximized and long-term clinical conditions. Dermatology. 1999;199(1):57-60.
Giguère V, Ong ES, Segui P, et al. Identifi cation of a receptor for the morphogen retinoic acid. Nature. 1987;330:624-629.
Gemma Latter, Jerey E. Grice, Yousuf Mohammed et al. Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems. Pharmaceutics. 2019;11(10):490. doi:10.3390/pharmaceutics11100490.
Gilchrest BA. A review of skin aging and its medical therapy. Br J Dermatol. 1996;135:867-875.
Green LJ, McCormick A, Weinstein GD. Photoaging and the skin: the effects of tretinoin. Dermatol Clin. 1993;11:97-105.
Green C, Orchard G, Cerio R, et al. A clinicopathological study of the effects of topical retinyl propionate cream in skin photoaging. Clin Exp Dermatol. 1998;23:162-167.
Griffiths CEM, Finkel IJ, Tranfaglia MG, et al. An in-vivo experimental model for topical retinoid effects on human skin. Br J Dermatol. 1993;29:389-399.
Griffiths C.EM, Kang S, Ellis CN, et al. Two concentrations of topical tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation. Arch Dermatol. 1995;131:1037-1044.
Griffiths CEM. Dowling Oration delivered at the Royal College of Physicians, London, Retinoids: renaissance and reformation. Clin Exp Dermatol. 1998;24:329-335.
Griffiths CE, Maddin S, Wiedow O, et al. Treatment of photoaged skin with a cream containing 0,05% isotretinoin and sunscreens. J Dermatol Treat. 2005;16:79-86.
Han HS, Kwon YJ, Park MS, et al. Efficacy validation of synthesized retinol derivatives in vitro: stability, toxicity, and activity. Bioorg Med Chem. 2003;11:3839-3945.
Hernandez-Perez E, Khawaja H, Alvarez T. Oral isotretinoin as part of the treatment of cutaneous aging. Dermatol Surg. 2000;26:649-652.
Hyung SJ, Deroo S, Robinson CV. Retinol and retinol-binding protein stabilize transthyretin via formation of retinol transport complex. ACS Chem Biol. 2010;5:1137-1146.
Jenning V, Gysler A, Schäfer-Korting M, et al. Vitamin A loaded solid lipid nanoparticles (SLN) for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm. 2000;49:211-218.
Jenning V, Schäfer-Korting M, Gohla S. Vitamin A loaded solid lipid nanoparticles (SLN) for topical use: drug release properties. J Control Rel. 2000b;66:115-126.
Jenning V, Gohla S. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul. 2001;18:149-158.
Jick SJ, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet. 1993;341:1181-1182.
Kambayashi H, Odake Y, Takada K, et al. N-retinoyl-Dglucosamine, a new retinoic acid agonist, mediates topical retinoid efficacy with no irritation on photoaged skin. Br J Dermatol. 2005;153:30-36.
Kang S, Duell EA, Fisher GJ, et al. N-retinoyl-Dglucosamine, a new retinoic acid agonist, mediates topical retinoid efficacy with no irritation on photoaged skin. Br J Dermatol. 1995;153:30-36.
Kang S, Duell EA, Fisher GJ, et al. Application of retinol to human skin in vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of retinoic acid but without measurable retinoic acid levels or irritation. J Invest Dermatol. 1995;105:549-556.
Kang S, Fisher G, Voorhees JJ. Photoaging: Pathogenesis, prevention and treatment. Clin Ger Med. 2001;17:643-659.
Kang S, Leyden JJ, Lowe NJ, et al. Tazarotene cream for the treatment of facial photodamage. Arch Dermatol. 2001;137:1597-604.
Kang S, Goldfarb M, Weiss J, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: A randomized trial. J Am Acad Dermatol. 2003;49:83-90.
Kang S, Krueger GG, Tanghetti EA, et al. A multicenter, randomized, double-blind trial of tazarotene 0,1 % cream in the treatment of photodamage. J Am Acad Dermatol. 2005;52:268-274.
Kim BH, Lee YS, Kang KS. The mechanism of retinol-induced irritation and its application to anti-irritant development. Toxicol Lett. 2003;146:65-73.
Kim MS, Lee SR, Rho HS, et al. The effects of a novel synthetic retinoid, seletinoid G, on the expression of extracellular matrix proteins in aged human skin in vivo. Clin Chimica Acta. 2005;362:161-169.
Kircik LH, Draelos ZD, Berson DS. Polymeric emulsiontechnology applied to tretinoin. J Drugs Dermatol. 2019;18(4):148-154.
Kligman LH, Chen HD, Kligman AM. Topical retinoic acid enhances the repair of ultraviolet damaged dermal connective tissue. Connect Tissue Res. 1984;12:139-150.
Kligman AM, Grove GL, Hirose R, et al. Topical tretinoin for photoaged skin. J Am Acad Dermatol. 1986;15:836-859.
Kligman AM. Is topical tretinoin teratogenic? [letter]. JAMA. 1988;259:2918.
Kligman AM, Dogadkina D, Lavker RM. Effects of topical tretinoin on the non-sun exposed protected skin of the elderly. J Am Acad Dermatol. 1993;29:25-33.
Kligman DE, Sadiq I, Pagnoni A, et al. High-strength tretinoin: a method for rapid retinization of facial skin. J Am Acad Dermatol. 1998;39:93-97.
Kligman DE, Draelos ZD. High-strength tretinoin for rapid retinization of photoaged skin. Dermatol Surg. 2004;30:864-866.
Krautheim A, Gollnick H. Transdermal penetration of topical drugs used in the treatment of acne. Clin Pharmacokinet. 2003;42:1287-1304.
Kurlandsky SB, Xiao JH, Duell EA, et al. Biological activity of alltrans retinol requires metabolic conversion to all-trans-retinoic acid and is mediated through activation of nuclear retinoid receptors in human kertinocytes. J Biol Chem. 1994;269:32821-32827.
Latriano L, Tzimas G, Wong F, et al. The percutaneous absorption of topically applied tretinoin and its effect on endogenous plasma tretinoin concentrations following single doses or long-term use. J Am Acad Dermatol. 1997;36:37-46.
Lever I, Kumar P, Marks R. Topical retinoic acid for treatment of solar damage. Br J Dermatol. 1990;122:91-98.
Leyden JJ, Grove GL, Grove MJ, et al. Treatment of photodamaged facial skin with topical tretinoin. J Am Acad Dermatol. 1989;21:638-644.
Leyden J. Adapalene in clincal practice. Cutis. 2001;68(4S):7-9.
Lowe N, Gifford M, Tanghetti E, et al. Tarazotene 0,1 % cream versus tretinoin 0,05 % emollient cream in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized, parallel-group study. J Cosmet Laser Ther. 2004;6:79-85.
Machtinger LA, Kaidbey K, Lim J, et al. Histological effects of tazarotene 0,1% cream vs. vehicle on photodamaged skin: a 6-month, multicentre, double-blind, randomized, vehicle-controlled study in patients with photodamaged facial skin. Br J Dermatol. 2004;151:1245-1252.
Maddin S, Lauharanta J, Agache P, et al. Isotretinoin improves the appearance of photodamaged skin: results of a 36-week, multicenter, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2000;42:56-63.
Massague J. TGF-β signal transduction. Ann Rev Biochem. 1998;67:753-791.
Massague J. How cells read TGF-β signals. Nat Rev. 2000;1:169-178.
Mordon S, Lagarde JM, Vienne MP, et al. Ultrasound imaging demonstration of the improvement of non-ablative laser remodeling by concomitant daily topical application of 0,05% retinaldehyde. J Cosmet Laser Ther. 2004;6:5-9.
Müller RH, Radtke S, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(S1);131-155.
Mukherjee S, Date A, Patravale V, et al. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327-334. doi:10.2147/ciia.2006.1.4.327.
Nagpal S, Athanikar J, Chandraratna RA. Separation of transactivation and AP1 antagonism functions of retinoic acid receptor alpha. J Biol Chem. 1995;270:923-927.
Nomenclature of retinoids. Recommendations 1981. Eur J Biochem. 1982;129:1-5.
Nyirady J, Bergfeld W, Ellis C, et al. Tretinoin cream 0,02 % for the treatment of photodamaged facial skin: A review of 2 double-blind clinical trials. Cutis. 2001;68:135-142.
Ochando N, LaGarde JM, Couval E, et al. Evaluation clinique et paraclinique des effets du rétinaldéhydetopique dans le Photovieillissementcutané. Nouv Dermatol. 1994;13:525-535.
Oda RM, Shimizu RW, Sabatine SC, et al. Effects of structural changes on retinoid cytotoxity in the CHO clonal assay. In vitro Toxicol. 1996;9:173-181.
Olsen EA, Katz I, Levine N, et al. Tretinoin emollient cream: a new therapy for photodamaged skin. J Am Acad Dermatol. 1992;26:215-24.
Olsen EA, Katz HI, Levine N, et al. Tretinoin emollient creamfor photodamaged skin: Results of 48-week, multicenter, double-blind studies. J Am Acad Dermatol. 1997a;37:217-216.
Olsen EA, Katz HI, Levine N, et al. Sustained improvement in photodamaged skin with reduced tretinoin emollient cream treatment regimen: Effect of once-weekly and three times-weekly applications. J Am Acad Dermatol. 1997;37:227-230.
Oppel T, Korting HC. Actinic keratosis: the key event in the evolution from photoaged skin to squamous cell carcinoma. Therapy based on pathogenetic and clinical aspects. Skin Pharmacol Physiol. 2004;17:67-76.
Orfanos CE, Zouboulis CC, Almond-Roesler B, et al. Current use and future potential role of retinoids in dermatology. Drugs. 1997;53:358-388.
Patravale VB, Shah K. Solid lipid nanoparticles based tretinoin gels using novel solvent emulsifi cation-diffusion (abstract P-39). Proceedings of the International Symposium on Advances in Technology and Business Potential of Novel Drug Delivery Systems. 2005;6:55.
Petkovich M, Brand MJ, Krust A, et al. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature. 1987;330:444-450.
Phillips TJ, Gottlieb AB, Leyden JJ, et al. Efficacy of 0,1 % tazarotene cream for the treatment of photodamage. A 12-month multicenter, randomized trial. Arch Dermatol. 2002:1486-1493. doi:10.1001/archderm.138.11.1486.
Szuts EZ, Hárosi FI. Solubility of retinoids in water. Arch Biochem Biophys. 1991;287:297-304.
Torok HM, Pillai R. Safety and ecacy of micronized tretinoin gel (0,05%) in tre adolescent acne. J Drugs Dermatol. 2011;10:647-652.
Tyring SK, Kircik LH, Pariser DM, et al. Novel Tretinoin 0,05 % Lotion for theOnce-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Assessment of Ecacy and Safety in Patients Aged 9 Years and Older. J Dermatol. 2018;17:1084-1091.
Voelker R. Tretinoin in New Lotion Formula. JAMA. 2018;320:1309.
Zasada M, Budzisz E. Retinoids: active molecules influencing skinstructure formation in cosmetic and dermatological treatments. Department of Cosmetic Raw Materials Chemistry, Faculty of Pharmacy, Medical University of Lodz, Lodz, Poland. Adv. Dermatol. Allergol. 2019;XXXVI (4):392-397.
Instruktsiia dlia medychnoho zastosuvannia likarskoho zasobu «Altreno»TM R.P. MOZ Ukrainy: N UA/18447/01/01 (Ukr.).
